The Dry Eye Syndrome Treatment Market was valued for $4,725.00 million in 2022 and is estimated to reach $9,316.50 million by 2032, exhibiting a CAGR of 7.1% from 2023 to 2032.
Dry eye disease is a common condition that occurs when a patient’s tears are unable to provide adequate lubrication for their eyes. Dry eye disease (DED), also known as dry eye syndrome (DES), keratoconjunctivitis sicca (KCS), and keratitis sicca, is a multifactorial disease of the ocular surface due to a loss of homeostasis of the tear film.
The growth of the dry eye syndrome treatment market is driven by rise in geriatric population, surge in prevalence of dry eye diseases, and increase in demand for effective treatment. In the geriatric people, there is decrease in efficiency of lacrimal glands to produce tears. Thus, lack of tears production leads to dry eye condition in geriatric people. For instance, according to the report published by the America’s Health Ranking by United Health Foundation, in 2021, it has been estimated that more than 54 million adults aged 65 and older live in the U.S., which is about 16.5% of the nation’s population.
Moreover, large medical technology firms have increasingly focused on acquiring companies that provide solutions for dry eye syndrome treatments, which is expected to notably contribute toward the market growth. Prominent players in the global dry eye syndrome treatment market have adopted various strategies such as product launches, acquisitions, and investments in R&D for advancement in dry eye syndrome treatments to strengthen their position in the market and sustain the competitive environment. For instance, in January 2023, Viatris Inc., a global healthcare company, announced its complete acquisition of Oyster Point Pharma and Famy Life Sciences to establish a new Viatris Eye Care Division.
Moreover, alarming increase in prevalence of dry eye diseases (DED), technological advancements in dry eye syndrome treatment, and long-term use of contact lens are some of the key factors that drive the growth of the market. Furthermore, extensive screen time and computer-based work notably contribute toward the growth in prevalence of dry eye syndrome (DES). However, stringent regulatory process for drug approval and dearth of skilled ophthalmologists may restrain the market growth. Conversely, increased application of dry eye syndrome treatment among the geriatric population and recent drug launched in market is expected to provide lucrative opportunities for the growth of the market in the near future. In addition, extensive R&D activities in the field of dry eye syndrome treatment along with significant improvement in medical infrastructure are anticipated to open new avenues for the expansion of the market during the forecast period.
The dry eye syndrome treatment market is segmented into drug, dosage form, distribution channel, and region. On the basis of drug, the market is classified into lubricant, dry eye syndrome drugs and others. On the basis of dosage form, the market is categorized into eye drops, ointments, and others. On the basis of distribution channel, it is classified into hospital pharmacies, retail pharmacies and online providers. On the basis of region, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major companies profiled in the report include Abbvie, Viatris, Novartis AG, Bausch & Lomb Incorporated, Sun Pharma, Novaliq, Santen Pharmaceutical Co., AFT Pharmaceuticals, Alcon and Johnson & Johnson.

KEY BENEFITS FOR STAKEHOLDERS
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the dry eye syndrome treatment market analysis from 2022 to 2032 to identify the prevailing dry eye syndrome treatment market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the dry eye syndrome treatment market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global dry eye syndrome treatment market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- New Product Development/ Product Matrix of Key Players
- Additional company profiles with specific to client’s interest
- Additional country or region analysis- market size and forecast
- Criss-cross segment analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
- SWOT Analysis

KEY MARKET SEGMENTS
By Drug
- Lubricant
- Dry eye syndrome drugs
- Others
By Dosage form
- Eye drops
- Ointments
- Other
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online providers

By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- AbbVie Inc.
- Viatris Inc.
- Novartis AG
- Bausch Health Companies Inc
- Novaliq
- AFT Pharmaceuticals Limited
- Alcon
- Johnson & Johnson (J&J)
- Santen Pharmaceutical Co., Ltd.
- Sun Pharmaceutical Industries Ltd.